Delcath Systems, Inc. has announced robust financial results for the third quarter of 2026, showcasing significant growth in revenue and net income. The company raised its revenue guidance for the full year, reflecting strong demand for its interventional oncology products. This update is crucial as it highlights Delcath’s expanding role in the surgical and medical instruments industry, particularly in the treatment of liver cancers.

Delcath Systems, Inc. (Nasdaq: DCTH), based in Queensbury, NY, focuses on developing treatments for primary and metastatic liver cancers. The company operates within the surgical and medical instruments and apparatus sector, as classified under SIC code 3841. Recent filings include an 8-K report on November 9, 2026, detailing financial results and business highlights for the quarter ending September 30, 2026.

The filing reveals that Delcath reported total revenue of $35.1 million for the third quarter, a substantial increase from $20.6 million in the same period last year. The revenue from the HEPZATO KIT™ reached $32.7 million, up from $19.3 million, while CHEMOSAT revenue also grew to $2.4 million from $1.3 million. Gross margins improved to 89%, compared to 87% in the previous year, and net income surged to $7.0 million from $0.8 million.

Delcath's financial performance reflects a growing interest in its innovative products, which are designed to enhance treatment options for patients with liver cancers. The company has also reported a non-GAAP adjusted EBITDA of $11.5 million for the quarter, compared to $5.3 million in Q3 2025, and cash provided by operations increased to $8.2 million from $4.8 million.

The filing indicates that Delcath currently operates 33 active treatment centers, with a 72% increase in HEPZATO volume compared to the same quarter last year. The company is advancing its clinical development pipeline, highlighted by the global Phase 2 DELUMA trial, which evaluates HEPZATO in combination with standard-of-care therapy for liver-dominant HER2-negative metastatic breast cancer.

Delcath's CEO, Gerard Michel, expressed confidence in the company's growth trajectory, stating, “We are pleased with the continued momentum in our business, with meaningful progress across both commercial operations and clinical development.” He also noted plans for an IND submission for cholangiocarcinoma in early 2027 and ongoing development of an oxaliplatin-based product.

Looking ahead, Delcath has raised its full-year revenue guidance to a range of $115 million to $117 million, reflecting an expected increase in HEPZATO KIT volume of at least 41% over 2025. The company anticipates maintaining gross margins between 87% and 89% for the year, alongside positive adjusted EBITDA.

The filing does not specify the next steps, but the positive financial results and guidance suggest a strong outlook for Delcath as it continues to expand its market presence and product offerings in the interventional oncology sector.